RE:RE:RE:RE:About The Neuramedy DealThe bottom line is that Bioasis is getting peanuts in its deals. They're getting nothing compared to the value of the drug/disease combinations that xB3-Drugs can enable.
Should we be looking for black helicopters? Why would Ladenburg Thalmann be looking for strategic opportunities and accretive mergers and acquisitions? Has Bioasis thrown in the towel on xB3? Is that what a deal like this signals?
No drug that has application for PD has a value this low. Remember this. Milestones are not paid for failure. They're paid for success - for milestones. Success in the pharmaceutical industry is a simple concept - the efficacious treatment of disease. No efficacy means no commercial value. The commercial value of the treatment of PD is likely billions or tens of billions per year. And Bioasis gets US $72 million, upon milestones. Unless the royalties are double digit, it doesn't seem like much.
You can dance on the head of a pin all you want, poff, make excuses, but the market says the deal was nothing, and I think it sucks, too.
Like I say, ask DrDR whether this is what xB3 is really worth, because that's what the deals are saying.
Sorry, folks, but I'm not getting this. It's better to do no deal than a bad deal.
jd